Promakhos Therapeutics is proud to announce the receipt of a Phase 1 Small Business Innovation Research (SBIR) Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This SBIR grant (1R43DK135153-01) provides $271,865 to support the preclinical development and validation of Promakhos' oral drug candidate for treating Crohn's disease. This candidate is designed to restore intestinal innate immune function and wound healing to resolve bowel inflammation without suppressing the immune system.

This is a news announcement supporting the original article published by the Big4Bio news aggregator on May 20, 2023. To learn more about Big4Bio, visit: https://big4bio.com/life-sciences-biotech-news/

Promakhos Therapeutics is excited to share that the company has been listed as a Life Sciences company to Watch by Big4Bio. Big4Bio is a premier aggregator of news and developments in the life sciences sector. Its name stands for the cornerstone “Big 4” in biosciences and health: drugs, devices, diagnostics, and digital (also known as the “four D’s”). Big4Bio produces individual summaries for the most significant life sciences markets in the world.

Promakhos Therapeutics is pleased to announce that the company has been selected as a Start-Up finalist for the 2023 BIO International convention.

Our CEO, Katerina Chatzi, will showcase and present our mission and vision on stage at the BIO 2023 Start-Up Stadium in Boston on Tuesday June 6th, 2023 11:00 AM-1:00 PM. We look forward to seeing you there!
‍

Promakhos Therapeutics has been selected as a finalist of the 2023 Harvard President's Innovation Challenge - Health & Life Sciences track. The Innovation challenge is a call to action, innovation and entrepreneurship – and an opportunity to win up to $75,000 (Grand Prize) or $25,000 (Runner-up) in non-dilutive funding. In May, Katerina Chatzi, our CEO, will present the company to a large audience at the Harvard Business School during the final event. We hope to see you there!

Promakhos Therapeutics is excited to announce that Dr. Mary Christian has joined the company's scientific advisory board.

Dr. Christian is a pharmaceutical and biotech executive who delivers visionary, innovative solutions in complex landscapes. She has a diverse experience in drug development spanning from regulatory strategy to establishing external partnerships with key academic institutions in the US to drive common research and development goals. She has created high functioning, fit-for-purpose teams for emerging biotech, envisioned and built new capabilities in large pharma (e.g. Bristol-Myers Squibb Oncology Strategic Collaborations, leading to success in >$50M in development partnerships), and led R&D efforts across a variety of therapeutic areas including but not limited to CNS, immunology, and immuno-oncology in all phases of development. She thrives where she is trusted, purpose-driven and ever-learning; strengths include collaborative problem solving, partnering for mutual success and diverse & inclusive leadership.                        

Dr. Christian is the Senior Vice President of Regulatory, Quality and Compliance at Lyndra Therapeutics, a rapidly growing clinical stage biotech whose mission is to reinvent medicine for a healthier world. Lyndra is developing a pipeline of long-acting oral therapies. The regulatory pathway to global approval is uncharted for products this unique; Dr. Christian is committed to leveraging 20+ years of regulatory and drug development experience, working with the stellar Lyndra team, to accelerate these important therapies to patients.  She also serves as a scientific advisor to several emerging biotech companies and lectures at MIT on Regulatory Strategies for developing drugs and devices.          

Prior to Lyndra, Dr. Christian was a founding team member of Cyclerion Therapeutics, a spinout of Ironwood Pharmaceuticals focused on serious and orphan diseases, where she led Regulatory, Quality and Pharmacovigilance.  She was Vice President of Global Regulatory Affairs at Ironwood Pharmaceuticals where she transformed the Regulatory organization and successfully negotiated approval of a stalled marketing application for Linzess® in China, advanced rare disease assets into Phase 1 and 2 and built organization models that enabled the spinoff.

Prior to joining the world of biotech in Boston, Dr. Christian created and led successful and innovative teams at Bristol-Myers Squibb by identifying novel ways to accelerate research and the delivery of medicines to patients globally. Dr. Christian also held roles of increasing responsibility in Global Regulatory Affairs at Johnson & Johnson Pharmaceutical Research & Development (now Janssen Pharmaceutica) across several therapeutic areas.                

This is a news announcement supporting the original article published by the Harvard Innovation Labs on April 18, 2022. To learn more about The Harvard Innovation Labs' mission, please visit: https://innovationlabs.harvard.edu/

In a new interview by the Harvard Innovation Labs, Dr. Katerina Chatzi discusses the history and mission of Promakhos Therapeutics.

‍

‍

This is a news announcement supporting the original article published by Nasdaq on January 12, 2022 and curated by Ladderworks. To learn more about Ladderworks' and Nasdaq's mission to stimulate equitable entrepreneurship and to inspire children to become social entrepreneurs, visit: https://www.ladderworks.co/ and https://www.nasdaq.com/Purpose

In this new interview with interplanetary journalist Spiffy, reporting for Nasdaq and Ladderworks, Promakhos Therapeutics' Dr. Katerina Chatzi talks about the company’s commitment to make a difference in the world. Dr. Chatzi also provides additional insight into Promakhos Therapeutics' history.

Promakhos Therapeutics has closed its first round of financing after participating in the summer 2021 batch of Y Combinator, a Silicon Valley accelerator. The newly raised funds will be used to support preclinical drug development and to establish a pipeline for the discovery of new molecules for the treatment of chronic inflammatory diseases. The round was backed by various angel investors and large biotech funds.

Promakhos Therapeutics is proud to announce that Dr. Joshua Korzenik and Dr. Jean-Frédéric Colombel have joined the company's scientific advisory board.

Dr. Korzenik is a visionary and specialist in Gastroenterology, Hepatology and Endoscopy that is well recognized for his compassion and dedication to his patients. He brings over 25 years of experience in clinical research that focuses on developing new therapies for inflammatory bowel disease and primary sclerosing cholangitis. His insights in Crohn’s disease and ulcerative colitis have opened new avenues of research and possible therapies, and he was among the first investigators to research the intestinal microbiome for clues about the role it may play in the development of inflammatory bowel disease as well as in its management through nutrition and therapeutics. Dr. Korzenik is an author of over 100 peer-reviewed articles and research papers and frequently speaks at professional meetings. He was named Humanitarian of the Year in 2013 by the New England Chapter of the Crohn’s and Colitis Foundation of America and was awarded the Torch of Friendship in 1999 by the Mid-America Chapter in St. Louis. Moreover, he has sequentially been selected as a Top Doctor by Boston Magazine in 2016, 2017, 2019, 2020 and 2021. He is currently an Assistant Professor of Medicine at Harvard Medical School, the Director of the Crohn's and Colitis Center at Brigham and Women’s Hospital and the Director of the Resnek Family Center for Primary Sclerosing Cholangitis Research at Brigham and Women’s Hospital.

Dr. Colombel is a world-renowned specialist in gastroenterology and immunology and a leading authority in inflammatory bowel disease. He has been leading inflammatory bowel disease research for over 35 years and implements and leads major clinical trials. Dr. Colombel was previously the President of the European Crohn’s and Colitis Organization (ECCO) (2008–2010) and Chair of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) (2010–2012). He has been awarded the United European Gastroenterology Federation (UEGF) Research Prize in 2009, the Crohn’s and Colitis Foundation (CCF) Clinical Research Award in 2014 and the Sherman Prize in 2018. His research is perhaps most well-known for his contributions to the identification of major susceptibility genes for the development of Crohn's disease, the identification of a new subtype of Escherichia coli associated with Crohn's disease, as well as the development of the Anti-Saccharomyces Cerevisiae Antibody (ASCA) test. Dr. Colombel has authored over 980 peer-reviewed papers, is a current associate editor of Gastroenterology and has also been an associate editor of other major gastroenterology journals including Gut and Alimentary Pharmacology and Therapeutics. Currently, Dr. Colombel serves as a Professor of Medicine at the Icahn School of Medicine at Mount Sinai, the Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center and the Director of the Leona M. and Harry B. Helmsley Charitable Inflammatory Bowel Disease Research Center.

Both Dr. Korzenik and Dr. Colombel are valuable additions to our team and we are pleased to be working with them.

Promakhos Therapeutics is thrilled to announce that the company has been selected to become an official resident of the Pagliuca Harvard Life Lab.

Promakhos Therapeutics presented its vision to the 9-member Harvard Life Lab Selection Committee, which included leading experts in the life sciences, renowned faculty members of the Harvard ecosystem, the Dean of Harvard Medical School and the Harvard Medical School Executive Director of Therapeutics Translation. After deliberation by the selection committee, Promakhos Therapeutics was then accepted as an official resident of the Pagliuca Harvard Life Lab.

About the Pagliuca Harvard Life Lab
The Pagliuca Harvard Life Lab is a fully equipped, shared wet laboratory space accompanied by a collaborative co-working office space for early-stage biotech and life science start-ups founded by Harvard students, alumni, faculty, and postdoctoral fellows. The Pagliuca Harvard Life Lab is part of the Harvard Innovation Labs and is located at Harvard's Allston Campus in Massachusetts, near the Harvard Business School. As part of the Harvard Innovation Labs ecosystem, ventures at the Harvard Pagliuca Life Lab have continued access to the business-building and industry-specific programming and the mentors and advisors available at the Harvard Innovation Labs. 

The Pagliuca Harvard Life Lab was made possible by the support and generosity of Judy and Stephen Pagliuca and is operated in partnership with LabCentral.